Canadian Government Criticizes Lilly for Patent Filings

Feb 16, 2015

Wall Street Journal

The Canadian government harshly criticized Eli Lilly in a patent dispute that is being heard by an international tribunal, according to an article in the Wall Street Journal. At issue, it says, is the extent to which a government has the right to set its own patent laws and the recourse a drug maker has to challenge unfavorable court decisions.

The battle began because of rulings a few years ago by Canadian courts that invalidated patents on two Lilly drugs – Zyprexa and Strattera. The decisions triggered cheaper generics in Canada, leading to what Lilly claims were significant sales and job losses there, the article said. Read the WSJ story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments